Fig. 2: Clonal distribution in tumors.

The relative proportion of individual IMP-R clones in untreated tumors (A) and tumors subjected to various drug regimens (B) is illustrated by charts, with values expressed as percentages of the total. The table provides clone-specific mutations in BCR::ABL1 and other leukemia-related genes that were acquired during imatinib/ponatinib resistant clone establishment.